Medco is running a comparative effectiveness study of Plavix vs Effient trial, in which patients in the Plavix arm are genotyped for their CYP2C19 status. (http://clinicaltrials.gov/ct2/show/NCT00995514). Medco is trying to prove non-inferiority of Plavix in normal CYP2C19 metabolizers. If it works out for Medco, by the time Plavix goes of patent, simple genotyping test can distinguish those who can take cheap generics from those who cannot. Now, can you see a link to Medco's Plavix/heartburn trial that made you suspicious?
News 
Market Data 
Discover 
